GenSight Biologics
54 articles with GenSight Biologics
-
BioSpace Global Roundup, Oct. 10
10/10/2019
Companies from across the globe provide updates on their business and pipelines. -
GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapy
10/9/2019
First study to find direct evidence that therapeutic gene is transferred from the injected eye to the uninjected contralateral eye of primates
-
GenSight Biologics Appoints Magali Taiel as Chief Medical Officer
10/8/2019
GenSight Biologics announced the appointment of Magali Taiel, MD, as Chief Medical Officer, effective immediately.
-
Clinical Catch-Up: September 23-27
9/30/2019
It was a moderately busy week for clinical trial news. Here’s a look. -
BioSpace Global Roundup, Sept. 26
9/26/2019
Companies from across the globe share updates on their business and pipelines. -
RESCUE and REVERSE are two separate but parallel Phase III trials evaluating the efficacy of a single intravitreal injection of GS0101 in patients with LHON from the G11778A mutation in the mitochondrial ND4 gene.
-
GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)
9/23/2019
GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported the first set of results from Week 96 of the RESCUE Phase III clinical trial.
-
GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule
7/11/2019
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that enrollment in REFLECT, a Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
-
Sustained Bilateral Improvement from GenSight Biologics’ REVERSE Phase III Clinical Trial Represents Transformative Therapeutic Benefit for Patients, Key Opinion Leaders Conclude
5/29/2019
GenSight Biologics reported highlights from its recent Key Opinion Leader panel hosted in New York City on May 23, 2019.
-
Here's a roundup of some of the top clinical trial news from the previous week.
-
BioSpace Global Roundup, May 16
5/16/2019
Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more. -
The 96-Week data showed continued efficacy of GS010 two years after injection, with best-corrected visual acuity (BCVA) holding a clinically meaningful improvement over baseline.
-
GenSight Biologics Reports Positive 96-Week Data from REVERSE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)
5/15/2019
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported a first set of results from Week 96 of the REVERSE Phase III clinical trial.
-
GenSight Biologics Announces Positive Data Safety Monitoring Board Review and Continuation of PIONEER Phase I/II Clinical Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa
5/7/2019
GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its first safety review of the ongoing PIONEER Phase I/II clinical trial of GS030 combining gene therapy and optogenetics for the treatment of Retinitis Pigmentosa.
-
GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
5/6/2019
GenSight Biologics announced that the 72-week results from the REVERSE Phase III clinical trial of GS010 will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, Pennsylvania, United States, May 4-10, 2019.
-
GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE & RESCUE Phase III Trials of GS010 at the Annual Meeting of ARVO
4/25/2019
GenSight Biologics announced that the 72-week results from the REVERSE and RESCUE Phase III clinical trials of GS010 will be presented at the 2019 Association for Research in Vision and Ophthalmology Annual Meeting in Vancouver, Canada, from April 28 to May 2, 2019.
-
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
-
GenSight Biologics Reports Positive Follow-up Results at Week 72 of the RESCUE Phase III Clinical Trial of GS010 in Leber Hereditary Optic Neuropathy (LHON)
4/17/2019
GS010-treated eyes showed continuous recovery of visual functions from nadir (worst vision post-treatment) in both best-corrected visual acuity (BCVA) and contrast sensitivity (CS)
-
GenSight Biologics Announces Presentation of 72-Week Data From the REVERSE Phase III Trial of GS010 at the 45th Annual Meeting of NANOS
3/15/2019
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today that the 72-week results from the REVERSE Phase III clinical trial of GS010 will be presented at the 45th Annual Meeting of the North American Neuro-Ophthalmology Society
-
GenSight Biologics Announces Publication of Positive Safety Data from Phase I/II Trial of GS010 in the JAMA Ophthalmology
2/12/2019
Intravitreal administration of GS010 in patients with LHON was safe and well tolerated